[ET Net News Agency, 10 August 2020] Daiwa Research cut its target price for Fosun
International (00656) to HK$12 from HK$14 and maintained its "buy" rating.
The research house sees Fosun's HealthTech and FinTech edge as being its cross-border
abilities, distinguishing it from domestic HealthTech players. Daiwa said Fosun is
actively utilising technology in its customer-to-maker (C2M) strategy across its health
ecosystem.
Learning from Fidelidade's experience in insurance and healthcare collaboration in
Portugal, Fosun United Health has started to explore product opportunities in
collaboration with private hospital brands under Fosun Pharma, and United Family
Healthcare, a leading integrated health and wellness solution provider in China.
Daiwa cut its 2020-22 EPS forecasts by 1-33% to factor in the ongoing impact on Fosun's
Happiness business from the continued near-suspension of cross-border travel globally.
(KL)